



Docket No. 55508 (45487)

RECEIVED
#25
SEP 07 2001
TECH CENTER 1600/2900
GAC 1683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Bjarne Due Larsen
SERIAL NO.: 09/341,590 EXAMINER: D. Lukton
FILED: July 13, 1999 GROUP NO.: 1653
FOR: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES
HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC
HYDROLYSIS

THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, DC 20231

CERTIFICATE OF MAILING

I, Patricia A. Barnes, hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office, as First Class Mail, postage prepaid, on August 31, 2001 in an envelope addressed to: The Assistant Commissioner of Patents, Washington, DC 20231.

Patricia A. Barnes
Patricia A. Barnes

SIR:

PETITION TO ACCORD CORRESPONDENCE FILING DATE SHOWN
ON EXPRESS MAIL LABEL "DATE-IN"

This is a Petition to accord the correspondence in the above-identified patent application the "date-in" of July 12, 1999 as shown on Express Mail Label No. EJ445393127US. It is respectfully submitted that the date of July 13, 1999 accorded to this correspondence by the USPTO is not correct.

09/06/2001 RHARIS1 00000099 041105 09341590
01 FC:122 130.00 CH

RECEIVED
SEP 21 2001
OFFICE OF PETITIONS

STATEMENT OF FACTS

1. The above-referenced patent application was deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee", Mailing Label EJ445393127US addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on July 12, 1999.

Attached to this Petition as **Appendix A** is a true copy of the Express Mail mailing label showing the "date-in" of July 12, 1999. 37 CFR 1.10 (c) (3).

2. The signed Certificate of Express Mail for the application indicates that the date of deposit was July 12, 1999 and not July 13, 1999.

Attached to this Petition as **Appendix B** is a true copy of the first page of the patent application that was filed, showing both the July 12, 1999 date on which the application was mailed as Express Mail Label No. EJ445393127US and that the number of the Express Mail was placed thereon prior to mailing pursuant to 37 CFR 1.10 (c) (2).

3. Applicants enclosed a self-addressed stamped post-card with the patent application that was received by Applicants with the incorrect July 13, 1999 mailing date. Attached as **Appendix C** is a true copy of the post card.

4. Applicants received an official PTO filing receipt showing the incorrect July 13, 1999 filing date. Attached to this Petition as **Appendix D** is a copy of that filing receipt showing that erroneous filing date.

5. The undersigned became an attorney of record in the above-referenced patent less than 1 year ago. Attached as **Appendix E** is a copy of that submission (Revocation of Prior Powers of Attorney and New Power of Attorney; Statement Under 37 CFR 3.73(b); and Assignment).

RELIEF REQUESTED

Accordingly, Applicants request that a filing date of July 12, 1999 be accorded to the above-referenced patent application.

The undersigned believes that the present Petition and its attachments are being promptly submitted following a recent inspection of the application file as received from the prior attorney of record (Cheryl Agris).

Kindly charge our deposit account no. 04-1105 the requisite petition fee of \$130.00. Should any further fee be needed to consider this submission, the USPTO is authorized to charge the deposit account for such fee.

Respectfully submitted,



Robert L. Buchanan (Reg. 40,927)
EDWARDS & ANGELL, LLP
DIKE, BRONSTEIN, ROBERTS & CUSHMAN
Intellectual Property Practice Group
P. O. Box 9169
Boston, MA 02209
Tel. (617) 439-4444
Fax: (617) 439-4170 / 7748

Date: 31 AUGUST 2001

#176686

RECEIVED

SEP 21 2001

OFFICE OF PETITIONS

RECEIVED

SEP 07 2001

TECH CENTER 1600/2900




UNITED STATES POSTAL SERVICE™

POST OFFICE TO ADDRESSEE

EJ445393J27US

PO ZIP Code		Day of Delivery		First Rate Envelope	
<input type="checkbox"/> First		<input type="checkbox"/> Next		<input type="checkbox"/> Second	
Postage		Return Receipt Fee		Insurance Fee	
Weight lbs. ozs.		Int'l Alpha Country Code		COD Fee	
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday <input type="checkbox"/>		Acceptance Clerk Initials		Total Postage & Fees \$	

SEE REVERSE SIDE FOR
SERVICE GUARANTEE AND
INSURANCE COVERAGE LIMITS



Customer Copy

APPENDIX A

CUSTOMER USE ONLY

METHOD OF PAYMENT:

Express Mail Corporate Acct. No. _____

Federal Agency Acct. No. or _____

Postal Service Acct. No. _____

FROM: (PLEASE PRINT) **PHONE** **914 312-0015**

TO: (PLEASE PRINT) **PHONE** _____

ASSISTANT COMMISSIONER

Box 100

Washington, D.C. 20031

FOR PICKUP OR TRACKING CALL 1-800-222-1811

www.usps.gov

Label 11-B July 1997



RECEIVED

SEP 21 2001

OFFICE OF PETITIONS

APPENDIX B

Attorney Docket No.: PPT-20479-US

PATENT

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

INTERNATIONAL APPLICATION NO. PCT/DK99/00118

INTERNATIONAL FILING DATE: March 9, 1999

PRIORITY DATE: March 9, 1998

TITLE: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A
REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

APPLICANT(S) FOR RO/US: Bjarne Due Larsen

EXPRESS MAIL CERTIFICATE


Assistant Commissioner for Patents
Box PCT
Washington, D.C. 20231

Sir:
Express Mail Label No. EJ445393127US
Date of Deposit July 12, 1999

I hereby certify that the following attached paper(s) or fee

1. Transmittal Letter to the DO/EO/US
2. Preliminary Amendment
3. Check for \$807.00
4. Copy of international application
5. Declaration and Power of Attorney
6. Assignment Recordation Cover Sheet
7. Assignment
8. Verified Statement Claiming Small Entity Status

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, DC 20231.

Cheryl H. Agris
(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing address:

P.O. Box 806
Pelham, N.Y. 10803
(914) 712-0093

RECEIVED

SEP 21 2001

OFFICE OF PETITIONS

APPENDIX C

516 Rec'd PGT/PTO

13 JUL 1999

Attorney Docket No. PPT-20479-US
Patent Application entitled: "PHARMACOLOGICALLY ACTIVE PEPTIDE
CONJUGATES HAVING A REDUCED TENDENCY
TOWARDS ENZYMATIC HYDROLYSIS"

Applicants: Larsen

09/341590

The USPTO hereby acknowledges receipt of the following:

1. Express Mail Certificate
2. Transmittal Letter to the DOZEO/US
3. Preliminary Amendment
4. Filing Fee (\$807.00)
5. Copy of international application (as filed)
6. Assignment Recordation Cover Sheet
7. Assignment
8. Verified Statement Claiming Small Entity Status

July 12, 1999


JUL 21 1999

BY: *C. Agris*

10575 U.S. PTO



07/13/99



Cheryl H. Agris Ph.D.
Attorney at Law
P.O. Box 808
Pelham, N.Y. 10803



FILING RECEIPT



APPENDIX D

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	NO C
09/341,590	07/13/99	1711	\$870.00	PPT-20479-US	0	39	

CHERYL H AGRIS
PO BOX 806
PELHAM NY 10803

JAN 20 1999

C. Agis

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice," the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) BJARNE DUE LARSEN, BRONSHOJ, DENMARK.

CONTINUING DATA AS CLAIMED BY APPLICANT-

THIS APPLN IS A 371 OF PCT/DK99/00118 03/09/99

FOREIGN APPLICATIONS- DENMARK 0317/98 03/09/99

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 01/13/00 ** SMALL ENTITY **
TITLEPHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY
TOWARDS ENZYMATIC HYDROLYSIS

PRELIMINARY CLASS: 530

DATA ENTRY BY: NGUYEN, SON

TEAM: 11 DATE: 01/13/00

(See reverse for new important information)

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE ---- The Following Information about the Filing Receipt:

The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

The words "new," "improved," "improvement," "improvements in or relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement.

The title may be truncated if it consists of more than 4 lines of 70 characters each (letters and spaces combined).

The inventor information may be truncated if the family name consists of more than 25 characters (letters and spaces combined) and if the given name consists of more than 25 characters (letters and spaces combined). The inventor's residence allows for up to 40 characters (letters and spaces combined).

The docket number allows a maximum of 12 characters.

If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Customer Address may have been modified to conform to U.S. Postal rules.

Please direct correction, including a copy of your Filing Receipt, to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

APPENDIX E

Attorney Docket No. PPT-20479-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Bjarne Due Larsen EXAMINER: N/A
SERIAL NO.: 09/341,590 GROUP: 1711
FILED: July 13, 1999

FOR: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED
TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on December 26, 2000.

By: _____

Donna M. Tomaso

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Sir:

RECEIVED

SEP 21 2001

OFFICE OF PETITIONS

TRANSMITTAL LETTER

Applicants submit the following documents as follows:

- 1) Revocation of Prior Powers of Attorney and New Power of Attorney.
- 2) Statement Under 37 CFR 3.73(b) – Establishing Right of Assignee to Take Action.
- 3) Assignment (copy).

Bjarne Due Larsen
USSN: 09/341,590
Page 2

The Commissioner is hereby authorized to charge any fees which may be required to Deposit Account No. **04-1105**.

Respectfully submitted,

Date: December 26, 2000

By: 

Robert L. Buchanan
Reg. No. 40,927
Attorney for Applicant(s)

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
130 Water Street
Boston, Massachusetts 02109
(617) 523-3400
160228



FORM 12-2

12-19

TECH CENTER 1600/2900

SEP 07 2001

RECEIVED

Practitioner's Docket No. PPT-20479-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

☒ In re application of: Bjarne Due Larsen
Application No.: 09 /341,590 Group No.: 1711
Filed: July 13, 1999 Examiner: N/A
For: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A
REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS
☐ Patent No*: Issued:

*NOTE: Insert name(s) of inventor(s) and title also for patent.

Assistant Commissioner for Patents
Washington, D.C. 20231

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST
(REVOCATION OF PRIOR POWERS);

As assignee of record of the entire interest of the above identified.

- ☒ application,
☐ patent.

RECEIVED

SEP 21 2001

OFFICE OF PETITIONS

REVOCATION OF PRIOR POWERS OF ATTORNEY

all powers of attorney previously given are hereby revoked and

NEW POWER OF ATTORNEY

the following attorney(s) and/or agent(s) are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith.

(list name and registration number)

David G. Conlin, Reg. No. 27,026	Peter F. Corless, Reg. No. 33,860
George W. Neuner, Reg. No. 26,964	Robert L. Buchanan, Reg. No. 40,927
Linda M. Buckley, Reg. No. 31,003	Kerri Pollard Schray, Reg. No. 47,066

(check the following item, if applicable)

- ☒ Attached, as part of this power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s).

SEND CORRESPONDENCE TO:

Robert L. Buchanan
EDWARDS & ANGELL, LLP
DIKE, BRONSTEIN, ROBERTS & CUSHMAN
130 Water Street
Boston, MA 02109-4280

(617) 523-3400

Customer No.: 21874

Zealand Pharmaceuticals A/S
(type or print identity of assignee of entire interest)

Smedeland 26B, DK-2600

Address

Glostrup, Denmark☒ Recorded in PTO on July 13, 1999Reel 010458Frame 0498☐ Recorded herewith**ASSIGNEE STATEMENT**

Attached to this power is a "STATEMENT UNDER 37 C.F.R. § 3.73(b)."


SignatureDate December 20, 2000Dr. Eva Steiness(type or print name of person authorized to
sign on behalf of assignee)President and CEO

Title

NOTE: The assignee of the entire interest may revoke previous powers and be represented by an attorney of
his or her selection. 37 C.F.R. § 1.36.

(check the following item, if it forms a part of this power of attorney)

☒ Added page—Authorization of attorney(s) to accept and follow instructions from
representative.

(Power of Attorney by Assignee of Entire Interest [12-2]—page 2 of 2)

(Re 1.77—109% Pub. 605)

FORM 12-2

12-21

**ADDED PAGE TO POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE
INTEREST FOR AUTHORIZATION OF ATTORNEY(S) TO ACCEPT AND
FOLLOW INSTRUCTIONS FROM REPRESENTATIVE**

The undersigned to this power of attorney hereby authorize(s) the U.S. attorney(s) named herein to accept and follow instructions from

Marianne Spanget Larsen
Name(s) of authorized representative(s)

Smedeland 26B, DK-2600
Address

Glostrup, Denmark

as to any actions to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney(s) and the undersigned. In the event of a change in the person(s) from whom instructions may be taken, the U.S. attorney(s) will so be notified by the undersigned.

(Rel. 75-598 Pub. 600)

FORM 16-16

16-69

Practitioner's Docket No. PPT-20479-US**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Bjarne Due Larsen

Application No.: 09 / 341,590 Group No.: 1711

Filed: July 13, 1999 Examiner: N/A

For: PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED
TENDENCY TOWARDS ENZYMATIC HYDROLYSIS

Issue Date: _____

Patent*: _____

Issue Date: _____

Reexamination No.: _____

Issue Date: _____

Reissue: _____

*NOTE: Insert name(s) of inventor(s) and title for patent.

Assistant Commissioner for Patents
Washington, D.C. 20231**STATEMENT UNDER 37 C.F.R. § 3.73(b)—
ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION****CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10***
(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING☐ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

37 C.F.R. § 1.8(a)

☒ with sufficient postage as first class mail.

37 C.F.R. § 1.10*

☐ as "Express Mail, Post Office to Addressee"

Mailing Label No. _____ (mandatory)

TRANSMISSION☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: December 26, 2000Donna M. Tomaso

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by Express Mail must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. § 1.10(b).

*Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

in a patent application, . . . , patent, registration, or reexamination proceeding, the assignee must establish its ownership of the property to the satisfaction of the Commissioner. Ownership is established by submitting to the Office, in the Office file related to the matter in which action is sought to be taken, documentary evidence of a chain of title from the original owner to the assignee (e.g., copy of an executed assignment submitted for recording) or by specifying (e.g., reel and frame number) where such evidence is recorded in the Office. The submission establishing ownership must be signed by a party authorized to act on behalf of the assignee. Documents submitted to establish ownership may be required to be recorded as a condition to permitting the assignee to take action in a matter pending before the Office."

NOTE: "Section 3.73(b) is amended to remove the sentence requiring an assignee to specifically state that the evidentiary documents have been reviewed and to certify that title is in the assignee seeking to take action. The sentence is deemed to be unnecessary in view of the amendment to §§ 1.4(c) and 10.18." Notice of Oct. 10, 1997, 62 Fed. Reg. 53,131, at 53,174.

1. The assignee(s) of the entire right, title and interest hereby seek(s) to take action in the PTO in this matter.

IDENTIFICATION OF ASSIGNEE

2. Zealand Pharmaceuticals A/S

Name of assignee

Corporation

Type of assignee, e.g., corporation, partnership, university, government agency, etc.

PERSON AUTHORIZED TO SIGN

3. Eva Steiness

(Type name of person authorized to sign on behalf of assignee)

President and CEO

Title of person authorized to sign

NOTE: The Notice of April 30, 1993 (1150 O.G. 62-64) points out:

"The statement under 37 CFR 3.73(b) may be signed on behalf of the assignee in the following two manners if the assignee is an organization (e.g., corporation, partnership, university, government agency, etc.).

"(1) The statement may be signed by a person in the organization having apparent authority to sign on behalf of the organization. An officer (president, vice-president, secretary, or treasurer) is presumed to have authority to sign on behalf of the organization. The signature of the chairman of the board of directors is acceptable, but not the signature of an individual director. A person having a title (manager, director, administrator, general counsel) that does not clearly set forth that person as an officer of the assignee is not presumed to be an officer of the assignee or to have authority to sign the statement on behalf of the assignee. A power of attorney from the inventors in an organization to a practitioner to prosecute a patent application does not make the practitioner an official of an assignee or empower the practitioner to sign the statement on behalf of the assignee.

"(2) The statement may be signed by any person, if the statement includes an averment that the person is empowered to sign the statement on behalf of the assignee and, if not signed by a registered practitioner, the statement must be in oath or declaration form. Where a statement does not include such an averment, and the person signing does not hold a position in the organization that would give rise to a presumption that the person is empowered to sign the statement on behalf of the assignee, evidence of the person's authority to sign will be required."

[Author's Note: The requirement for an oath or declaration for this statement by a person not a registered practitioner was rescinded by the rules effective December 1, 1997.]

(complete the following, if applicable)

☒ I, the person signing below, state that I am empowered to sign this statement on behalf of the assignee.

(Statement under 37 C.F.R. § 3.73(b) — Establishing Right of Assignee to Take Action [16-16]—page 2 of 4)

(Re. 175-598 Pub. 6051)

FORM 16-16

16-71

BASIS OF ASSIGNEE'S INTEREST

Ownership by the assignee is established as follows:

A.

1. ☒ An assignment from the inventor(s) of the matter identified above, which was recorded in the PTO at
Reel 010458, Frame 0498
2. ☐ An assignment (document) separately being submitted for recordal herewith.

AND/OR**B.** ☐ A chain of title from the inventor(s) to the current assignee as shown below:1. From: _____
Name of Inventor(s)

To: _____

Recorded in PTO: Reel _____
Frame _____2. From: _____
Name of Inventor(s) or assignee

To: _____

Recorded in PTO: Reel _____
Frame _____3. From: _____
Name of Inventor(s) or assignee

To: _____

Recorded in PTO: Reel _____
Frame _____*(check item below, and add details, if applicable)*

- ☐ Additional documents in the chain of title are listed in the attached Supplemental Sheet.

COPIES OF DOCUMENTS IN CHAIN OF TITLE*(complete this item, if copies are being sent)*

- ☒ Copies of the assignment(s) or other document(s) in the chain of title are attached as follows:

☒ A☒ 1☐ 2☐ B☐ 1☐ 2☐ 3




(Signature of authorized person)

Eva Steiness

(type or print name of authorized person)

President and CEO

Title of authorized person



SIGNATURE OF PRACTITIONER

Robert L. Buchanan

(type or print name of practitioner)

EDWARDS & ANGELL, LLP

DIKE, BRONSTEIN, ROBERTS & CUSHMAN

P.O. Address

Intellectual Property Practice Group
130 Water St., Boston, MA 02109-4280


Reg. No.: 40,927

Tel. No.: (617) 523-3400

Customer No.: 21874

MARCH 20, 2000

CHERYL H. AGRIS
ATTORNEY AT LAW
P.O. BOX 806
PELHAM, N.Y. 10803



PTAS

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231



101235993A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 07/13/1999

REEL/FRAME: 010458/0498
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

LARSEN, BJARNE DUE

DOC DATE: 07/09/1999

ASSIGNEE:

ZEALAND PHARMACEUTICALS A/S
AGERN ALLE 3
DK-2970 HORSHOLM, DENMARK


SERIAL NUMBER: 09341590

FILING DATE: 07/13/1999

PATENT NUMBER:

ISSUE DATE:

SHAREILL COLES, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



RECEIVED

SEP 21 2001

OFFICE OF PETITIONS

MMS
6/13/99

A 10581-40
01-03-2000

09/341590
09/25 PCT/PTO 13 JUL 1999

PTO-1595 RECORDATION FOR
REV. 6-93) U.S. DEPARTMENT
OMB No. 0651-0011 (exp. 4/94)



101235993

DEPT OF COMMERCE

To the Hon. Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Bjarne Due Larsen

Additional name(s) of conveying party(ies) attached? () Yes (x) No

2. Name and address of receiving party(ies):

Name: Zealand Pharmaceuticals A/S

Internal Address:

Street Address: Agern Allé 3
DK-2970 Hørsholm Denmark

Additional name(s) & address(es) attached? () Yes (x) No

3. Nature of conveyance:

(x) Assignment () Merger

() Security Agreement () Change of Name

() Other _____

Execution Date: _____

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the filing date of the provisional application is: _____

A. Patent Application No.(s) filed concurrently herewith

B. Patent No.(s)

Additional numbers attached? () Yes (x) No

09/341590

5. Name and address of the party to whom correspondence concerning document should be mailed:

Name: Cheryl H. Agnis, Ph.D.
Attorney at Law
P.O. Box 806
Pelham, N.Y. 10803

6. Total number of applications and patents involved: one

7. Total fee (37 CFR 3.41) \$ 40.00

(x) Enclosed

() Authorized to be charged to deposit account

8. Deposit account number:

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Cheryl H. Agnis
Name of Person Signing

Signature

Cheryl H. Agnis 7/12/99

Date

Total number of pages including cover sheet, and document: 3

Docket No. PPT-20479-US

PATENT

ASSIGNMENT OF APPLICATION FOR PATENT

WHEREAS: Bjarne Due Larsen, a citizen of Denmark, residing at Arildsgård 5, 1.th, DK-2700 Brønshøj Denmark

(hereinafter ASSIGNOR), has made a discovery or invention entitled:
PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED
TENDENCY TOWARDS ENZYME HYDROLYSIS for which application of Letters Patent of
the United States has been filed:

☒ concurrently herewith

☐ was filed as U.S. Application No. _____ on _____

and

WHEREAS:

ZEALAND PHARMACEUTICALS A/S a corporation organized under the laws DENMARK, located at Agern Allé 3, DK-2970 Hørsholm Denmark, is desirous of acquiring the entire interest in, to and under said invention and in, to and under Letters Patent or similar legal protection to be obtained therefor in the United States and in any and all foreign countries.

NOW, THEREFORE, in consideration of the payment by ASSIGNEE to ASSIGNOR of the sum of one dollar (\$1) or the equivalent thereof, the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE, its successors, legal representatives and assigns, the full and exclusive right, title and interest to said discovery or invention in the United States and its territorial possessions and in all foreign countries and to all Letters Patent or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for said invention by said application or any continuation, division, continuation-in-part, renewal, extension, substitute or reissue thereof or any legal equivalent thereof in a foreign country for the full term or terms for which the same may be granted.

SAID ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States of America and any Official of any country or countries foreign to the United States of America whose duty it is to issue Letters Patent on applications as aforesaid, to issue all such Letters Patent for said discovery or invention to the ASSIGNEE, as assignee of the entire right, title and interest in, to and under the same, for the sole use and behalf of the ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

RECEIVED

SEP 2 1 2001

OFFICE OF PETITIONS

SEP 1 JUL 21 07:10:10

SAID ASSIGNOR hereby covenants that I have full right to convey the entire right, title and interest herein sold, assigned, transferred and set over.

AND SAID ASSIGNOR hereby further covenants and agrees that the ASSIGNEE, its successors, legal representatives, and assigns, may apply for foreign Letters Patent on said discovery or invention and claim the benefits of the International Convention, and that I will, at any time, when called upon to do so by the ASSIGNEE, its successors, legal representatives, or assigns, communicate to the ASSIGNEE, its successors, legal representatives, or assigns, as the case may be, any facts known to me respecting said discovery or invention, and execute and deliver any and all lawful papers that may be necessary or desirable to perfect the title to the said discovery or invention, the said applications and the said Letters Patent in the ASSIGNEE, its successors, legal representatives and assigns, and that if reissues of the said Letters Patent or disclaimers relating thereto, or divisions, continuations, or refilings of the said applications, or any thereof, shall hereafter be desired by the ASSIGNEE, its successors, legal representatives or assigns, I will, at any time, when called upon to do so by the ASSIGNEE, its successors, legal representatives, or assigns, sign all lawful papers, make all rightful oaths, execute and deliver all such disclaimers and all divisional, continuation and reissue applications so desired, and do all lawful acts requisite for the application for such reissues and the procuring thereof and for the filing of such disclaimers and such applications, and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said invention or discovery in all countries, all without further compensation but at the expense of the ASSIGNEE, its successors, legal representatives and assigns.

Date:

9/7/93


BJARNE DUE LARSEN

RECEIVED

SEP 21 2001

OFFICE OF PETITIONS